Financial Data and Key Metrics Changes - Bausch Health reported a revenue increase of 9% in Q4 2025, reaching $2,796 million compared to the same quarter in 2024 [11] - Adjusted EBITDA for Q4 was $1,052 million, reflecting a 13% year-over-year increase [11] - For the full year 2025, revenue grew by 7% and adjusted EBITDA increased by 10% [19] Business Line Data and Key Metrics Changes - Salix revenue in Q4 was $693 million, a 9% increase year-over-year [14] - Solta Medical segment revenues were $137 million, a slight decrease of 1% year-over-year, impacted by distributor transition [16] - Diversified segment revenues increased by 12% to $255 million, primarily due to improved net pricing [17] Market Data and Key Metrics Changes - International segment revenues were $306 million, a 10% increase on a reported basis, with mixed results across geographies [15] - EMEA and Latin America showed double-digit growth, while Canada contracted by 6% due to increased generic competition [15] Company Strategy and Development Direction - The company aims to enhance operational assets through innovation and optimize brand growth globally [23] - Bausch Health is focused on business development opportunities to expand its portfolio and maximize shareholder value [23] - The acquisition of XiBo strengthens the company's presence in the Chinese aesthetics market, a key growth area [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in future growth, citing strong performance across markets and improved capital structure [6][7] - The company anticipates a stronger growth rate in the first half of 2026, with a revenue guidance of $5.25 billion to $5.4 billion [21][22] - Management acknowledged the disappointment regarding the RED-C trial results but emphasized ongoing focus on debt repayment and business reinvestment [34] Other Important Information - The company achieved over $1 billion in adjusted operating cash flow for the year and reduced net debt by approximately $320 million in Q4 [8][14] - The debt maturity profile was improved by approximately $1.7 billion through a debt exchange [8] Q&A Session Summary Question: What is the updated decision framework for the separation post RED-C readout? - Management stated there is no change in focus, continuing to prioritize debt repayment and business reinvestment [34] Question: Can you provide more details about business development plans? - Management is screening assets for potential acquisitions, leveraging their strong commercial team [37] Question: What are the expected impacts of the Shibo integration on revenue and EBITDA growth? - The integration is progressing smoothly, with some accounting impacts expected in Q4 [44][46] Question: What is the outlook for Xifaxan generics and exclusivity? - Management is focused on maximizing Xifaxan's value and is monitoring ongoing legal proceedings regarding generics [86] Question: How will EBITDA shape up in 2027 relative to 2025? - Management reiterated that 2026 and 2027 EBITDA would be similar to 2025, with expected growth platforms to offset declines [66]

Financial Data and Key Metrics Changes - Bausch Health reported a revenue increase of 9% in Q4 2025 compared to Q4 2024, reaching $2,796 million, with adjusted EBITDA rising by 13% to $1,052 million [10][11] - For the full year 2025, revenue grew by 7% and adjusted EBITDA by 10%, indicating strong operational performance [18][19] - Adjusted gross margin was 71.6%, down 80 basis points year-over-year, while adjusted operating expenses increased by $75 million to $1,033 million [10][11] Business Line Data and Key Metrics Changes - Salix revenue in Q4 was $693 million, a 9% increase year-over-year, driven by strong demand and promotional efforts [12] - Solta Medical segment revenues decreased by 1% to $137 million, impacted by distributor transition in China, but would have shown mid-single-digit growth without this effect [15][16] - The diversified segment saw a 12% revenue increase to $255 million, primarily due to improved net pricing [16] Market Data and Key Metrics Changes - International segment revenues were $306 million, up 10% on a reported basis, with EMEA and LatAm showing double-digit growth, while Canada contracted by 6% [13][14] - The Latin American market returned to growth with a 22% revenue increase, while Canada faced challenges due to increased generic competition [14][15] Company Strategy and Development Direction - The company aims to enhance operational assets through innovation and optimize brand growth globally, with a focus on business development opportunities [21][22] - The acquisition of Shibo's aesthetics distribution platform in China is expected to strengthen the company's market presence and enhance direct engagement with providers [7][26] - Strategic priorities for 2026 include maximizing shareholder value and optimizing the capital structure following significant refinancing [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in future growth, citing strong cash generation and improved capital structure, allowing for proactive business development [5][7] - The company anticipates a stronger growth rate in the first half of 2026, with a revenue guidance range of $5.25 billion to $5.4 billion [20][21] - Management acknowledged the disappointment regarding the RED-C trial results but remains focused on advancing other development opportunities [9] Other Important Information - The company achieved over $1 billion in adjusted operating cash flow for the year and reduced net debt by approximately $320 million in Q4 [7][12] - The debt maturity profile was improved by approximately $1.7 billion through a debt exchange, providing additional flexibility for future opportunities [7][19] Q&A Session Summary Question: Post RED-C readout, what is the updated decision framework for separation and debt repayments? - Management stated there is no change in focus, continuing to prioritize debt repayment and reinvestment in the business [33] Question: Can you provide more details about business development plans? - Management is screening various assets for potential acquisitions, leveraging their strong commercial team [36][37] Question: What is the impact of the Shibo integration on revenue and EBITDA growth? - The integration is progressing well, with a minor EBITDA impact of $10-$15 million due to accounting adjustments [45][47] Question: What are the expectations for Xifaxan generics? - Management confirmed that a generic is expected by January 1, 2028, and is focused on maximizing current value [84] Question: What is the EBITDA trajectory for 2027? - Management indicated that 2027 EBITDA would likely be around $2.7 billion, reflecting a dip compared to 2025 [86]

Core Insights - Bausch Health reported a consolidated adjusted EBITDA of $1.05 billion for Q4 2025, a 13% increase, and $3.54 billion for the full year, a 7% increase [1][2] - The company achieved consolidated revenues of $10.27 billion for the full year 2025, up 7% on a reported basis and 5% on an organic basis [1][2] - The fourth quarter revenues reached $2.80 billion, reflecting a 9% increase on a reported basis and a 6% increase on an organic basis compared to Q4 2024 [1][2] Financial Performance - The consolidated net loss attributable to Bausch Health for Q4 2025 was $112 million, compared to a net income of $93 million in Q4 2024 [2] - For the full year 2025, the company reported a net income of $157 million, a significant improvement from a net loss of $46 million in 2024 [2] - Consolidated operating income for Q4 2025 was $474 million, down from $558 million in Q4 2024, primarily due to a goodwill impairment charge of $145 million [2] Segment Performance - The Salix segment reported revenues of $693 million for Q4 2025, a 9% increase, and $2.58 billion for the full year, an 11% increase [1][2] - The International segment generated $306 million in Q4 2025, a 10% increase, and $1.13 billion for the full year, a 2% increase [1][2] - The Bausch + Lomb segment reported revenues of $1.41 billion for Q4 2025, a 10% increase, and $5.10 billion for the full year, a 6% increase [2] Cash Flow and Debt Management - The company generated $495 million in cash from operating activities in Q4 2025, down from $601 million in Q4 2024 [2] - Total cash provided by operating activities for the full year was $1.40 billion, compared to $1.60 billion in 2024 [2] - Bausch Health executed a $1.7 billion debt exchange offer in Q4 2025, extending debt maturities to 2032 [1][2] Strategic Developments - The acquisition of Shibo's full-service aesthetics distribution business in China was completed on December 1, 2025, enhancing the company's market presence [1] - The company continues to focus on strengthening its balance sheet and enhancing shareholder value [2] - Bausch Health is committed to operational excellence and expanding its portfolio as it moves into 2026 [1][2]

Core Viewpoint - Bausch Health Companies is facing challenges due to a significant patent cliff and recent setbacks, but it may present a long-term investment opportunity for patient investors [1][2][6]. Company Performance - Bausch Health shares have declined by 17% since the beginning of 2026, with a current market cap of $2.1 billion [1][3]. - The stock price is currently at $5.69, with a day's range of $5.58 to $5.79 and a 52-week range of $4.25 to $8.69 [3]. Patent and Product Developments - The company is approaching a major patent cliff with its blockbuster drug Xifaxan, losing exclusivity in 2029, while generic versions are expected to launch in 2028 [5]. - Efforts to expand Xifaxan's label for treating cirrhosis have faced setbacks due to a failed phase 3 clinical trial [6]. Potential Catalysts - Two potential inflection points for Bausch Health include a skin-tightening treatment from its Solta unit and the hepatitis treatment Larsucosterol, acquired through the 2025 acquisition of Durect Corporation [8]. - The company's stake in Bausch + Lomb, valued at approximately $5.2 billion, significantly exceeds its current market cap, representing a key underlying value [9]. Management and Investor Involvement - Bausch Health's management previously rejected an offer to sell the eye health unit to a private equity buyer, indicating a focus on long-term value [10]. - Activist investor involvement, particularly from John Paulson, has not accelerated the monetization of assets, despite his significant shareholding since 2022 [11].

Core Insights - Bausch Health Companies Inc. reported its tenth consecutive quarter of revenue and adjusted EBITDA growth, with a 7% year-over-year revenue increase on a reported basis and a 5% increase on an organic basis for the third quarter of 2025 [5][7][11] - The company raised its full-year guidance for revenue, adjusted EBITDA, and adjusted cash flow from operations due to strong performance in the first nine months of the year [6][18][19] Financial Performance - Consolidated revenue for the third quarter was $2.681 billion, reflecting a 7% increase on a reported basis and a 5% increase on an organic basis compared to the same period last year [10] - Adjusted EBITDA was $986 million, an increase of $77 million or 8% year-over-year, while adjusted operating cash flow was $508 million [10] - For Bausch Health excluding Bausch + Lomb, revenue was $1.4 billion, up 7% on a reported basis and 5% on an organic basis, with adjusted EBITDA of $773 million, reflecting a 7% increase [11][12] Segment Performance - The Solta and Salix businesses showed strong performance, with Solta achieving 25% growth and Salix achieving 12% growth on a reported basis [7][12] - XIFAXAN revenue grew 16% in the third quarter, driven by volume growth and a strong marketing campaign [12][23] - The International segment saw mixed performance, with EMEA growing by 12% while Canada and LATAM experienced declines of 8% and 17%, respectively [14] Strategic Initiatives - The company closed its acquisition of Direct Corporation, enhancing its R&D pipeline and focusing on innovation to drive future growth [30] - Bausch Health is committed to optimizing its capital structure, having reduced debt by approximately $600 million [6][21] - The company is focused on executing its five strategic priorities: people, growth, efficiency, innovation, and unlocking value [22] Guidance and Outlook - Full-year revenue is now expected to be between $5 billion and $5.1 billion, representing a 4% increase year-over-year [18] - Adjusted EBITDA outlook is now expected to be between $2.7 billion and $2.75 billion, indicating a 7% increase versus 2024 [19] - Adjusted operating cash flow is projected to be between $975 million and $1.025 billion, reflecting a $150 million increase in the midpoint of the range [19]

Core Insights - Bausch Health reported third quarter consolidated revenues of $2.68 billion, reflecting a 7% increase on a reported basis and a 5% increase on an organic basis compared to the prior year [1] - The company achieved a GAAP net income attributable to Bausch Health of $179 million and a total GAAP net income of $181 million [1] - Consolidated adjusted EBITDA attributable to Bausch Health was $986 million, which includes an $81 million charge for acquired in-process research and development (IPR&D), marking an 8% increase on a reported basis year-over-year [1] - Excluding Bausch + Lomb, Bausch Health delivered its tenth consecutive quarter of year-over-year revenue and adjusted EBITDA growth, with reported revenue growth of 7% and adjusted EBITDA growth of 7% [1] - The company raised its full-year 2025 guidance for revenue, adjusted EBITDA, and adjusted cash flow from operations [1] - Bausch Health completed the acquisition of DURECT Corporation, enhancing its hepatology portfolio with the addition of Larsucosterol, a novel epigenetic modulator designated as a Breakthrough Therapy by the FDA for the treatment of alcohol-associated hepatitis [1]